As President and CEO, Kevin has led the Welldoc® team in the successful launch and continued development of digital therapeutics for people living with chronic disease. Kevin oversees all Welldoc business related to enterprise strategy and has engineered an innovative commercial approach to position WellDoc in the marketplace to attract key investors, like Johnson & Johnson, Samsung and Merck GHI. He has also established key strategic partnerships that include Johnson & Johnson, Samsung, Solera, Voluntis and American Well.
Prior to joining Welldoc in 2014, Kevin had an extensive career in biotech and pharmaceuticals. He held senior executive roles at Human Genome Sciences, Genentech and Abbott after beginning his career at Baxter Healthcare.